- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Home > Press > Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit: Alexandra Glucksmann Invited to Highlight Company’s Progress in Applying Nanotechnology in the Life Sciences
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that Alexandra Glucksmann, Ph.D., the Company's Senior Vice President, Research and Business Operations, will present at the Nanotechnology Innovation Summit being organized by the Nano Science and Technology Institute (NSTI) in celebration of the 10th anniversary of the National Nanotechnology Initiative (NNI). The Summit is being held in Washington, D.C., from December 8-10, 2010.
Dr. Glucksmann has been invited to give an address in the Innovations in Life Science Technologies session of the Summit. In her address, she will highlight Cerulean's advancement of first-in-class nanopharmaceutical drug candidates in pre-clinical and clinical development. Additionally, Dr. Glucksmann will showcase the unique potential of Cerulean's nanopharmaceutical platform to enhance efficacy of therapeutic agents while maintaining high quality of life for patients. Dr. Glucksmann will present at 11:10 a.m. EST on Friday, December 10, 2010 in the Gaylord National Hotel and Convention Center in Washington, D.C.
The Summit is gathering leaders in nanotechnology research and development as well as in policy and finance. Other invited speakers include representatives from the White House, federal government departments and agencies, academic institutes, and industry, who will discuss the latest developments and innovations in nanotechnology. The NNI was established in 2001 with the vision of advancing leadership in nanotechnology through collaborations and dedicated funding.
About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.
For more information, please click here
Andrew Law/Benjamin Navon
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016